Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-88545223 in Active Psoriatic Arthritis
NCT07321873Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of JNJ-88545223 in psoriatic arthritis (PsA) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 50 Response at 16 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
JNJ-88545223
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07321873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321873.